The importance of studies to evaluate the inflammatory status in COPD has increased since the launching of new drugs, such as an oralphosphodiesterase 4 (PDE4) inhibitor with systemic effects and appears to offer the potential to target the inflammatory processes underlying COPD [14]. Here, PDE4A is linked to chronic obstructive pulmonary disease.